New Parkinson's treatment approved in the U.S

A new treatment for Parkinson's disease may help millions manage their symptoms more effectively. The adaptive Deep Brain Stimulation (aDBS) therapy has recently received approval for regular use in the U.S. It offers a significant advancement over earlier methods that have been in place since 1997. The therapy involves a battery-powered device that sends electrical currents to electrodes in the brain, helping to alleviate symptoms like stiffness and tremors associated with Parkinson's disease. Keith Krehbiel, diagnosed with young-onset Parkinson’s at age 42, became the first person in the U.S. to receive this therapy as part of his regular care. Parkinson's disease affects around 10 million people worldwide, and diagnoses have doubled since the 1990s. Experts predict that by 2050, the number of people with the disease could reach 25 million. In the U.S., there are approximately 1 million people living with Parkinson's and about 90,000 new cases each year. The development of this new therapy began in 2011 when researchers partnered with Medtronic, a medical device company. The therapy has since undergone rigorous testing and has shown promising results. Krehbiel, who has experienced significant improvement, noted he has reduced his medication intake and feels better overall, even as his symptoms continue to progress. Another recipient of the treatment, John Lipp, has also seen positive changes. Diagnosed in 2015, he no longer experiences severe muscle cramping and has resumed activities, including running marathons. Both Krehbiel and Lipp emphasize the importance of optimism, despite the ongoing challenges of living with Parkinson's. Experts believe that while there is currently no cure for Parkinson's disease, advances in symptom management like aDBS are crucial. The research team hopes to make this treatment accessible to everyone who needs it and continue to improve the care available for patients.